More than 200 people in nine states have reported bleeding or other symptoms associated with exposure to synthetic cannabinoid products containing an anticoagulant agent, including five who died, the Centers for Disease Control and Prevention reported Friday in an update on an outbreak that began in March. Most of the cases were in Illinois, and the rest in Maryland, Florida, Indiana, Kentucky, Missouri, Pennsylvania, Virginia and Wisconsin. Nearly all of the patients have tested positive for brodifacoum, a vitamin K antagonist anticoagulant, which public health officials believe may have been mixed with synthetic cannabinoid products, commonly referred to as synthetic marijuana, K2 or Spice. CDC said health care providers should screen patients presenting with unexplained bleeding and a possible history of synthetic cannabinoid for vitamin K-dependent antagonist coagulopathy, and report possible cases to their local health department, among other recommendations.

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded $15 million in Coronavirus Aid, Relief and Economic Security Act funds to 52 tribal health…
Headline
The COVID-19 pandemic has changed a lot across the health care landscape, including how care teams communicate, interact and collaborate with others. In this…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response yesterday released resources focused on…
Headline
The Food and Drug Administration May 27 authorized the emergency use of the Stryker Sustainability Solutions VHP N95 Respirator Decontamination System during…
Headline
The Federal Emergency Management Agency this month issued COVID-19 pandemic operational guidance for the forthcoming hurricane season. Included in the document…
Headline
A new Centers for Disease Control and Prevention study released today shows community transmission of COVID-19 in the U.S. was occurring in February of this…